INTRODUCTION
Bile acid diarrhoea (BAD) is a common and often missed cause of chronic watery diarrhoea. 1, 2 Bile acids facilitate lipid absorption in the small intestine and normally 95-97% are reabsorbed in the terminal ileum and recirculated to the liver. 3, 4 Non-absorbed bile acids promote colonic secretion causing liquid stools and bile acid diarrhoea. 5 BAD was first recognised in patients after resection of, or with disease in, the terminal ileum. Other conditions such as microscopic colitis 6 and cholecystectomy 7 may also cause secondary BAD. Primary BAD has no obvious accompanying pathology as originally described by Thaysen, 8 and due to similarity between symptoms of primary BAD and those of diarrhoea predominant irritable bowel syndrome (IBS-D), primary BAD is often misdiagnosed as IBS-D. 9, 10 The prevalence of primary BAD among IBS-D patients is approximately 32% 11, 12 and BAD is estimated to affect 1% of the general population.
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The diagnosis of BAD is currently based on the SeH-CAT test, which is a scintigraphic test of 75 Se taurine conjugated homocholic acid retention ( 75 Se-HCAT). 75 Se-HCAT circulates in the enterohepatic circulation and at each passage some is lost to the large intestine. 14 The seven-day retention of 75 Se-HCAT calculated as the fraction of day one emission is the result and by this BAD is arbitrarily classified as severe (<5%), moderate (5.0-10.0%) or mild (10.1-14.9%) but there is no consensus on cut-off values. 11 Patients with a SeHCAT retention of <15% usually have good response to therapy with bile acid sequestrants. 15 The SeHCAT test has limited availability and is not applicable as a screening test for BAD. However, two biochemical test candidates fibroblast growth factor 19 (FGF19) and 7a-hydroxy-4-cholesten-3-one (C4) have been identified. Bile acids reabsorbed in the terminal ileum are ligands of the nuclear farnesoid X receptor (FXR) that stimulates transcription of the hormone FGF19 which reaches the liver by the portal circulation, activates the hepatic FGF receptor 4 and inhibits the rate limiting cytochrome p450 enzyme cholesterol 7a-hydroxylase (CYP7A1). This downregulates de novo synthesis of bile acids. 16, 17 The intermediary bile acid C4 is a biomarker of bile acid synthesis, and patients with BAD have elevated C4. 18, 19 Measuring C4, however, requires high performance liquid chromatography with tandem mass spectrometry limiting its clinical availability, 14 while FGF19 is readily measured with enzyme-linked immunosorbent assay (ELISA). Walters and colleagues showed that FGF19 and C4 are inversely correlated, 20 and that patients with BAD have lower median fasting levels of FGF19 than diarrhoea controls. They proposed that a deficient FGF19 feedback may cause primary BAD and that FGF19 might be useful in the diagnosis of BAD. 21 However, fasting FGF19 alone has insufficient diagnostic power in a clinical context with a sensitivity of 58% and specificity of 84% for diagnosing BAD defined by SeHCAT <10%.
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Since postprandial FGF19 increases in healthy subjects, [22] [23] [24] [25] we hypothesised that this response would be impaired in BAD and supported this idea studying 26 patients prospectively referred to SeHCAT. 26 In the present study, we aimed to further augment and standardise the stimulation of FXR by adding the potent natural FXR agonist chenodeoxycholic acid (CDCA) 27 and aimed to evaluate how this new test and C4 discriminate between healthy volunteers and patients with primary BAD diagnosed by SeHCAT test.
MATERIALS AND METHODS

Participants
We recruited healthy volunteers from the hospital staff.
Patients with primary BAD diagnosed by a recent SeH-CAT test were invited by mail and we included five patients within 6 months of their SeHCAT test and three patients within 16 months. Exclusion criteria for all participants were pregnancy, breastfeeding, cholecystectomy, resection of the small intestine, right sided hemicolectomy, abdominal radiation therapy, ongoing treatment with statins, chronic diarrhoeal diseases including ulcerative colitis, Crohn's disease, and microscopic colitis. Sequestrants were not allowed 7 days prior to each study visit. Other anti-diarrheoals were allowed as rescue medication, however, none was utilised. We conducted the study in accordance with the Helsinki Declaration with approval from the Ethic Committee of the Zealand Region (SJ-279) and with monitoring from the Danish Data Protection Agency. All participants gave voluntary written informed consent.
Study design
This was an exploratory pilot study. After an overnight fast, participants attended Zealand University Hospital on three separate study visits at least 1 week apart. All participants kept a diary of bowel habits classified by the Bristol stool scale for 7 days ahead of each of the three study visits. At each visit, participants ingested one of these stimuli in the following nonrandomised order: (i) a meal plus 1250 mg CDCA by mouth, (ii) 1250 mg CDCA by mouth, (iii) the meal alone. CDCA (SigmaTau Arzneimittel GmbH, Munich, Germany) was unconjugated and ingested with 500 mL plain water. The meal was ingested within 15 min and consisted of two slices of white toast without spread (each slice of 36 g) and two hardboiled eggs each of 60 g. In total 1465 kJ with 14.1 g fat, 34.2 g carbohydrates, 21.3 g protein and a relative energy distribution of 35% fat, 40% carbohydrates, and 25% protein.
Sample preparation and analysis
We sampled fasting blood through a venous catheter for standard laboratory analyses: alanine aminotransferase, alkaline phosphatase, bilirubin, glucose, creatinine, cholesterols (high and low density lipoprotein, and total), triglycerides, and C-reactive protein. Fasting samples for FGF19, C4, and bile acid species were drawn and immediately centrifuged at 4°C. Participants then received the stimulus as described above, and repeated EDTA-plasma samples were drawn after 60, 90, 120, 150, 180, 210 and 240 min. These samples were frozen on dry ice and subsequently stored at À80°C.
Standard blood analyses were done at Zealand University Hospital. We analysed FGF19 by commercially available ELISA kit (R&D systems Minneapolis, Minnesota, MN, USA), with 7.4% coefficient of variation. C4 and bile acids were analysed in the laboratory of Dr. Rainteau by liquid chromatography-tandem mass spectrometry as previously described for bile acids 28 and for C4. 29 We report specific results for C4 and CDCA. Data on other bile acid species are pooled and reported as total, primary, and secondary bile acids. 
Statistics
RESULTS
Six primary BAD patients had SeHCAT <10% and the remaining two had SeHCAT of 10% and 11%. Patients with primary BAD had more loose and frequent stools than the healthy volunteers (Table 1) . Standard laboratory values were similar in the two groups, apart from fasting triglycerides as four primary BAD patients had values >1.9 mmol/L, but just one healthy volunteer (data not shown).
Fibroblast growth factor 19
Fasting FGF19 values on the three visits were similar for primary BAD patients (P = 0.76) with a coefficient of variation (CV) of 42%. For the healthy volunteers, fasting FGF19 values were also expected to be equal, but they were significantly higher before stimulation with the meal alone than on the meal plus CDCA visit (Table 2 ) (P = 0.003). These three fasting measurements had a CV of 52%. Fasting FGF19 was similar between primary BAD patients and healthy volunteers before stimulation with meal plus CDCA (P = 0.80). Following the stimulation in primary BAD patients, FGF19 transiently decreased and 
* BMI, body mass index; BAD, bile acid diarrhoea; IQR, interquartile range.
then slightly increased at 180 min. Conversely, median FGF19 increased in healthy volunteers and peaked at 150 min ( Figure 1a ). The increment in FGF19 (DFGF19) from fasting to 90 min after the CDCA plus meal stimulation separated the groups (P = 0.001) with a cut-off value of 2.3 pg/mL and ROC AUC of 1.0 (P = 0.001) ( Figure 2 ). Total area under FGF19 curves did not improve the discriminative value as compared with DFGF19 values (Table 2 and 3) . Receiver operating characteristics area under the curve (ROC AUC ) for fasting FGF19 was 0.55 [95% confidence interval (95% CI): 0.25-0.84; P = 0.75). Ninety min after stimulation with meal plus CDCA this increased to 0.84 (95% CI: 0.64-1.0; P = 0.02) ( Table 3) .
Fasting median FGF19 before stimulation with CDCA given alone did not differ between the healthy volunteers and primary BAD patients (P = 0.51), while the stimulation induced an FGF19 response with a peak in healthy volunteers after 240 min, that is, 90 min delayed compared with the meal plus CDCA stimulation. ROC AUC analysis of FGF19 at 240 min and DFGF19 from fasting to the 240 min peak both showed values of 0.75.
Median fasting FGF19 did not differ between healthy volunteers and the primary BAD patients (P = 0.11) before ingestion of the meal alone. The meal did neither affect FGF19 in healthy volunteers nor in patients with primary BAD. As the marginal separation of two otherwise flat graphs (Figure 1c ) persisted the FGF19 AUC differed significantly (P = 0.028), while the DFGF19 values did not (P = 0.96) ( Table 2) .
Stratification of primary BAD patients by triglyceride levels did not modify the results after any stimulation and no significant correlation was found by linear regression. Patients with primary BAD and hypertriglyceridemia did not have higher fasting, incremental or AUC values of FGF19.
Plasma C4
Plasma C4 was significantly higher in primary BAD patients ( Figure 3) . None of the stimuli affected C4, but given our sample size we would not detect small changes. The fasting C4 measurements had a CV of 45% for primary BAD patients and 65% for healthy volunteers. ROC AUC analysis of fasting C4 at the three visits gave 0.81 (95% CI: 0.59-1.0; P = 0.04), 0.95 (0.85-1.0; P = 0.002) and 0.94 (0.81-1.0; P = 0.003) ( Table 3) .
Plasma CDCA and bile acid species Plasma CDCA peaked 60 min after ingestion of the meal plus CDCA reaching 13.2 lmol/L (IQR: 6.9-19.1) in primary BAD patients and 20.5 lmol/L (IQR: 18.5-30.9) in healthy volunteers (P = 0.13). In the subsequent measurements, the healthy volunteers also had higher plasma levels of CDCA, which in the repeated measurements analysis was borderline significant (P = 0.011; Bonferroni corrected significance level P < 0.0018) (Figure 1d ), but of note this was not corrected for the difference in weight. Stimulation with oral CDCA alone delayed the plasma CDCA peak in both groups from 60 min to 120 min compared with meal plus CDCA stimulation. Peak values were similar but the differences in plasma CDCA were not significant (P = 0.61) (Figure 1e ). Plasma levels and fluctuations in other bile acids were similar between the two groups at all visits (supplementary data).
DISCUSSION
Currently, both lack of awareness of BAD and readily available diagnostic tools leave many patients with BAD undiagnosed. Screening for BAD in patients with chronic watery diarrhoea could be beneficial as the estimated overall prevalence of BAD is comparable to that of coeliac disease. 2 As the SeHCAT test cannot accommodate this, a simple biochemical test is preferable and to date the most promising candidates are C4 and FGF19. Analysis of C4 requires high performance liquid chromatography with tandem mass spectrometry limiting its broad clinical utilisation. 14 FGF19 is easily analysed but fasting values lack diagnostic power. In this pilot study, we demonstrated that the stimulated FGF19 response to a meal plus CDCA is impaired in primary BAD patients compared with healthy volunteers. In particular, stimulated DFGF19 could provide a diagnostic test and this merits a prospective validation with fasting C4 and SeH-CAT. Given alone CDCA caused a similar but delayed FGF19 response with corresponding delayed and suboptimal separation between the groups. The diagnostic characteristics of fasting FGF19 was studied in detail by Pattni and colleagues who found serum FGF19 < 145 pg/mL to have 58% sensitivity and 84% specificity for detecting BAD defined by SeHCAT <10% with ROC AUC of 0.74. 1 This diagnostic value of fasting FGF19 reflects the overlap between BAD and diarrhoea controls. We also demonstrated that fasting FGF19 was a poor predictor of primary BAD illustrated by ROC AUC values of 0.55, 0.61, and 0.75. This shows that fasting FGF19 levels were relatively low in the healthy volunteers on two out of our three visits. As in the present study, we have previously reported considerable intra-individual variation in fasting FGF19 in non-BAD subjects. 26 Low fasting values of FGF19 in non-BAD subjects is the primary limitation of FGF19 as a diagnostic test and this is why a stimulation-based test is appealing. Recent studies have explored the FGF19 response to different macronutrients in populations with heterogenic results. Johnston and colleagues found lower postprandial 6-hour FGF19 AUC in primary BAD patients with SeHCAT retention <5% than in patients with moderate and mild BAD. 23 This indicates an inverse relationship between the FGF19 response and the severity of BAD. Their breakfast had 20% fat energy and stimulated a small response in FGF19 while the lunch with 31% fat energy gave a larger response; however, the underlying diurnal variation complicates this interpretation. In another study, patients with type 2 diabetes and matched non-diabetic controls had little response in FGF19 to carbohydrates, but increasing responses to meals with higher lipid content which caused FGF19 to peak after 4 h. 25 In accordance with this, a large study found that FGF19 peaked four hours after stimulation with a carbohydrate-free oral lipid tolerance test, but there was no response to an oral glucose tolerance test. 30 Conversely, the same group earlier reported an FGF19 response 120 min after an oral glucose tolerance test. 31 Another group gave blinded liquid meals with different content of macronutrients and found a small response in FGF19 to lipids while carbohydrates were the superior stimulant of FGF19. 22 Thus, carbohydrates in some circumstances stimulate an FGF19 response after 120-150 min, while lipids more consistently elicit an FGF19 response after 3-4 h. The increase in endogenous bile acids precedes these responses by 1-2 h. 30, 31 The meal in our study was solid with a balanced content of macronutrients. Given alone, it caused a negligible increase in endogenous bile acids in plasma and did neither stimulate FGF19 nor improve the diagnostic characteristics of FGF19 (Table 2 and 3) . Had we used a higher lipid content in our meal, we might have seen a greater endogenous bile acid response and a late FGF19 response, but possibly at the price of a delayed and more varied CDCA stimulation due to lipid induced delayed gastric emptying. There is evidence that CDCA in itself delays gastric emptying in both patients with constipation predominant IBS 32 and in patients with type 2 diabetes. 33 We did not measure gastric emptying or intestinal transit time, but the time to peak in plasma CDCA that we report was identical for healthy volunteers and primary BAD patients, indicating that delayed gastric emptying is an unlikely cause of the difference in FGF19 response between these two groups. When comparing our results on CDCA given alone or together with the meal (Table 2) , it seems the meal propelled the CDCA forward. Further studies should examine the relation between gastrointestinal transit time, absorption of CDCA and FGF19 response. Direct stimulation of FGF19 through FXR agonists was recently studied with CDCA given without a meal to non-BAD patients 34 and our results in healthy volunteers mirror these findings with FGF19 peaking after four hours. In BAD patients, direct stimulation of FGF19 by the synthetic bile acid and potent FXR agonist obeticholic acid was examined in an exploratory trial of its possible therapeutic effects. 35 Administering 25 mg obeticholic acid caused an increase in 6-hour FGF19 AUC in primary BAD patients, and as expected patients with secondary BAD did not respond. Surprisingly, idiopathic diarrhoea controls had only half the response of patients with primary BAD. This is both in conflict with the results on meal stimulated FGF19 discussed above and with the results of our trial, where CDCA stimulated a greater FGF19 response in healthy volunteers than in primary BAD patients. The reason for this divergence is unknown, but although CDCA and obeticholic acid both are FXR agonists, one may speculate that in primary BAD, a defect in FXR signalling by natural bile acids could have caused upregulation of FXR signalling. If obeticholic acid bypasses such a defect, primary BAD patients could have a larger FGF19 response than diarrhoea controls. Studying variation in bile acid synthesis, G€ alman and colleagues found that 35% of patients with elevated C4, indicating primary BAD, also had hypertriglyceridemia. 36 In addition, Johnston and colleagues found that primary BAD patients with hypertriglyceridemia had higher fasting and postprandial increase in FGF19 than other BAD patients and proposed this to be a specific phenotype of primary BAD. 23 Four of our eight primary BAD patients had hypertriglyceridemia, but we could not reproduce this correlation in our small and selected sample. Active reabsorption of bile acids is normal or increased in ileal biopsies from patients with primary BAD, [37] [38] [39] and thus the current concept is that absorption of bile acids in primary BAD patients is normal. Reabsorption capacity is thought to be saturated and exceeded by pathologically increased synthesis of bile acids due to an impeded FGF19 feedback. 2, 40 Until now, this has not been studied in vivo. We found a tendency to lower plasma CDCA in patients with primary BAD compared with healthy volunteers after ingestion of meal plus CDCA (P = 0.011; nonsign. with Bonferroni correction) (Figure 1d ). Some unconjugated CDCA given by mouth was undoubtedly absorbed in the small intestine, but as the increase in plasma CDCA was coupled with subsequent increase in FGF19, ileal CDCA reabsorption and FXR activation is indicated. Systemic effects of passively absorbed CDCA are less likely. 41, 42 This suggests bile acid malabsorption in primary BAD, but this clearly needs replication as it simply may reflect the larger body weight of the primary BAD patients. A test for BAD based on a stimulated DFGF19 response rather than on fasting FGF19 alone would have several benefits of which increased specificity is the primary. Better identification of healthy volunteers with low fasting FGF19, but a normal stimulated response would give fewer false positive test results. Furthermore, utilising the difference between two blood samples in the same individual reduces assay variability. These benefits also apply to a test based on a total FGF19 AUC. Such a test is more laborious but seems more robust than a two-sample DFGF19 test. However, the improved diagnostic characteristics of FGF19 after CDCA plus meal lasted from 90-150 min, in which, DFGF19 ROC AUC was comparable to those for the total FGF19 AUCs. In any case, better understanding of the FGF19 physiology after stimulation should accompany efforts to develop such a test. The biochemical test alternative C4 has better separation between healthy subjects and BAD patients than FGF19, but requires analysis at a central laboratory. Our results confirm that C4 is a good marker of BAD 14 and C4 was unaffected by our stimulations in the 240 min observation period.
The choice of diagnostic test for BAD depends on diagnostic probabilities, availability and price. A systematic review and meta-analysis of tests for BAD in functional diarrhoea found that 17.1% had a positive C4 test, 24.8% had a positive fasting FGF19 test and 31% had a positive SeHCAT test, 13 but the concurrency between the tests could not be estimated. Further investigations of these tests and subsequent treatment response are lacking 15 and prospective and systematic comparisons of the putative diagnostic tests are mandatory considering the high prevalence of BAD. Empirical treatment with cholestyramine does not suffice as a diagnostic test for BAD. 43 Cholestyramine has a nonspecific sequestrant effect and could therefore alleviate diarrhoea from other causes than BAD and thus generate a false positive test result. Furthermore, a patient could report lack of effect because of the well-known side effects of cholestyramine resulting in a false-negative test result. Therefore, cholestyramine should preferably be prescribed to patients with a diagnosis of BAD based on a validated test or with BAD due to small intestinal resection. 44 Our study has inherent limitations. We compared participants with known severe to moderate primary BAD to healthy volunteers without diarrhoea. Selection bias and the healthy comparison group may have amplified the group differences even though our fasting FGF19 values concur with previous results. 1 Hence, further prospective studies should include diarrhoea controls. The small number of participants in our study increase the risk of type I error. Although our study meal did not elicit an FGF19 response on its own, it may have propagated a uniform stimulation by CDCA. In summary, this pilot study strengthened the hypothesis that an impaired stimulated FGF19 response may identify patients with primary BAD.
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